Optimization of the risk-benefit ratio of differentiated thyroid cancer treatment

Hani O. Nasef, Iain J. Nixon, Volkert B. Wreesmann*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


The vast majority of differentiated thyroid cancers (DTC) are characterized by an innocuous nature, excellent patient survival, and limited treatment requirement. However, a significant proportion of affected patients is prone to receiving overtreatment, due to undertreatment concerns associated with the difficulty to differentiate them from a small minority affected by aggressive DTC. Identification of prognostic factors and development of staging systems has helped to reduce the proportion of overtreatment in DTC. However, the absolute number of overtreated patients continues to increase, as a result of an on-going incidence surge in early DTC associated with the increased application and sensitivity of modern diagnostic tools. In the present paper, we describe how DTC treatment can be optimized by thoughtful evidence-based balancing of oncologic safety against treatment associated morbidity.

Original languageEnglish
Pages (from-to)276-285
Number of pages10
JournalEJSO - European Journal of Surgical Oncology
Issue number3
Publication statusPublished - 1 Mar 2018


  • Differentiated thyroid cancers
  • Treatment de-escalation


Dive into the research topics of 'Optimization of the risk-benefit ratio of differentiated thyroid cancer treatment'. Together they form a unique fingerprint.

Cite this